Benjamin Morgan Scirica MD
Senior Physician and Director, Innovation, Cardiovascular Division, Brigham and Women's Hospital; Professor of Medicine, Harvard Medical School; Senior Investigator, TIMI Study Group, Boston, MassachusettsDr. Benjamin Scirica is a senior physician and Director of Innovation in the Cardiovascular Division at Brigham and Women's Hospital and Professor of Medicine at Harvard Medical School. He is a Senior Investigator at the TIMI Study Group (an academic research organization based at Brigham and Women's Hospital that has performed over 75 clinical trials in cardiometabolic diseases).
His research interests center on the risk stratification, management, and the identifation of novel therapies to improve outcomes in patients with acute coronary syndromes and cardiometabolic disorders.
Dr. Scirica has authored or co-authored over 200 peer-reviewed articles and is a reviewer for multiple journals, including The New England Journal of Medicine, JAMA, The Lancet, Circulation, and Journal of the American College of Cardiology (JACC).
Disclosures
- Institutional research support to Brigham and Women’s Hospital from: Amgen; Better Therapeutics; Boehringer Ingelheim; Merck; Novo Nordisk; Pfizer; Verve Therapeutics
- Consulting fees from: AbbVie (DSMB); Amgen; AstraZeneca (DSMB); Bayer; Boehringer Ingelheim (DSMB); Elsevier Practice Update Cardiology; Hanmi (DSMB); Lexeo (DSMB); Novo Nordisk; Verve Therapeutics; and equity in Health [at] Scale; Arboretum Lifescience
Recent Contributions to PracticeUpdate:
- Effect of Dapagliflozin on LV Hypertrophy in Type 2 Diabetes
- ACC: Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
- ACC: The Role of Sodium Nitrite in Out-of-Hospital Cardiac Arrest
- ACC: Combination Anti-Platelet and Anticoagulation Therapy in High-Risk Patients With Diabetes
- ACC: New Insights on the Duration of DAPT Therapy Post-PCI From TWILIGHT
- Ticagrelor—With or Without Aspirin After Complex PCI?
- Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Undergoing PCI
- ACC: Improved Outcomes With Icosapent Ethyl in Updated REDUCE-IT Data
- Lipid Accumulation in Hearts Transplanted From Nondiabetic Donors to Diabetic Recipients
- Nonculprit Lesion Myocardial Infarction Following PCI in Patients With Acute Coronary Syndrome